DFTX Stock (DFTX) Opinions on BofA Coverage and Phase 3 Catalysts

By: Quiver DiscussionTracker

Posted: an hour ago / Aug. 25, 2026 2:04 p.m. UTC

Institutional Accumulation Signals: Recent 13F filings highlight continued buying by major holders including Octagon Capital and others, with one top position showing significant gains from average cost bases. Social media observers note over 450 institutions now hold shares, reflecting sustained interest amid upcoming trial data.

Analyst Coverage Boost: BofA Securities initiated coverage with a Buy rating and $75 price target, citing potential in DT120 for major depressive disorder and generalized anxiety disorder. Discussions emphasize the multi-billion-dollar opportunity if Phase 3 results in September confirm earlier positive outcomes.

Catalyst Watchlist Focus: DFTX appears prominently on biotech catalyst lists for its Phase 3 readout, with users discussing functional unblinding concerns from prior data and expectations for stronger performance in the Panorama trial. Sentiment remains cautiously optimistic around the durability of single-dose therapy.

Note: This discussion summary was generated from an AI condensation of post data.

DFTX Insider Trading Activity

DFTX insiders have traded $DFTX stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.

Here’s a breakdown of recent trading of $DFTX stock by insiders over the last 6 months:

• ROBERT BARROW (Chief Executive Officer) has made 0 purchases and 2 sales selling 53,639 shares for an estimated $1,766,476.
• MARK SULLIVAN (Chief Legal Officer) has made 0 purchases and 2 sales selling 23,710 shares for an estimated $783,416.
• DANIEL KARLIN (Chief Medical Officer) has made 0 purchases and 2 sales selling 18,053 shares for an estimated $599,968.
• BRANDI ROBERTS (Chief Financial Officer) sold 3,013 shares for an estimated $135,675
• MATTHEW T. WILEY (Chief Commercial Officer) sold 2,867 shares for an estimated $129,101

To track insider transactions, check out Quiver Quantitative’s insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

DFTX Hedge Fund Activity

We have seen 259 institutional investors add shares of DFTX stock to their portfolio, and 88 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• CAPITAL WORLD INVESTORS added 5,367,723 shares (+inf%) to their portfolio in Q2 2026, for an estimated $252,497,689
• PRICE T ROWE ASSOCIATES INC /MD/ added 4,582,031 shares (+6545.7%) to their portfolio in Q2 2026, for an estimated $215,538,738
• CAPITAL INTERNATIONAL INVESTORS added 2,963,410 shares (+inf%) to their portfolio in Q2 2026, for an estimated $139,398,806
• FMR LLC added 2,943,311 shares (+162.6%) to their portfolio in Q2 2026, for an estimated $138,453,349
• BLACKROCK, INC. added 2,752,604 shares (+32.5%) to their portfolio in Q2 2026, for an estimated $129,482,492
• AVORO CAPITAL ADVISORS LLC added 2,188,888 shares (+43.8%) to their portfolio in Q2 2026, for an estimated $102,965,291
• ALLIANCEBERNSTEIN L.P. added 1,711,584 shares (+1866.4%) to their portfolio in Q2 2026, for an estimated $80,512,911

To track hedge funds’ stock portfolios, check out Quiver Quantitative’s institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

DFTX Price Targets

Multiple analysts have issued price targets for $DFTX recently. We have seen 9 analysts offer price targets for $DFTX in the last 6 months, with a median target of $58.0.

Here are some recent targets:

• Paul Matteis from Stifel set a target price of $60.0 on 07/08/2026
• Sumant Kulkarni from Canaccord Genuity set a target price of $58.0 on 06/30/2026
• Justin Walsh from Jones Trading set a target price of $74.0 on 06/24/2026
• Christopher Chen from Baird set a target price of $57.0 on 06/23/2026
• Ami Fadia from Needham set a target price of $50.0 on 06/23/2026
• Marc Goodman from Leerink Partners set a target price of $52.0 on 06/22/2026
• Jay Olson from Oppenheimer set a target price of $60.0 on 06/22/2026

This article is not financial advice. See Quiver Quantitative’s disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.